<code id='999531B09B'></code><style id='999531B09B'></style>
    • <acronym id='999531B09B'></acronym>
      <center id='999531B09B'><center id='999531B09B'><tfoot id='999531B09B'></tfoot></center><abbr id='999531B09B'><dir id='999531B09B'><tfoot id='999531B09B'></tfoot><noframes id='999531B09B'>

    • <optgroup id='999531B09B'><strike id='999531B09B'><sup id='999531B09B'></sup></strike><code id='999531B09B'></code></optgroup>
        1. <b id='999531B09B'><label id='999531B09B'><select id='999531B09B'><dt id='999531B09B'><span id='999531B09B'></span></dt></select></label></b><u id='999531B09B'></u>
          <i id='999531B09B'><strike id='999531B09B'><tt id='999531B09B'><pre id='999531B09B'></pre></tt></strike></i>

          explore

          explore

          author:focus    Page View:548
          Cambridge: Biogen
          Ruby Wallau for STAT

          Biogen, the iconic but embattled biotech firm, is shuttering Biogen Digital Health, its roughly 150-person group focused on using new types of data like those from mobile phones and smart watches, and ending a clinical trial being conducted with Apple early, STAT has learned.

          Biogen confirmed the organizational change, but said it might lean even more on digital tech startups in the future.

          advertisement

          “It’s certainly not an abandonment of digital, it’s more of a realignment of resources and priorities,” said Adam Keeney, Biogen’s executive vice president and head of corporate development. However, he later acknowledged, Biogen Digital Health, a separate entity, “would no longer continue in its current form.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Affirmative action in medical school literally saved lives
          Affirmative action in medical school literally saved lives

          AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

          read more
          Insmed lung disease drug hits target in key Phase 3 trial
          Insmed lung disease drug hits target in key Phase 3 trial

          AdobeAnexperimentaldrugfromInsmedIncorporatedsuccessfullyreducedlungproblemsamongpatientswithanairwa

          read more
          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more

          Female surgeons have lower rates of long

          AdobeAnewstudypublishedWednesdayinJAMASurgerysuggeststhatpatientstreatedbyfemalesurgeonshavelowerrat